Diffuse large B-cell lymphoma: An institutional analysis

• DOI: 10.4103/sajc.sajc_65_18
• Publication Date: 2018-07-13T07:04:59Z
• Authors: Ajay Gogia; Chandan K. Das; Lalit Kumar; Atul Sharma; Akash Tiwari; M.C Sharma; Soumya Mallick
• Keywords: International Prognostic Index; Single Center; Histopathology; B symptoms

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin's lymphoma. We conducted a retrospective study to analyze clinicopathological characteristics, cell origin, response therapy, and outcome patients with DLBCL.This was which included all DLBCL registered at our center, between May 1, 2013, July 31, 2015. The data regarding demography, clinical presentation, histopathology, stage, prognostic index, treatment, treatment-related were collected from prospectively maintained case records patients.In study, we 267 patients. median age 49 (20-81) years male: female ratio 2:1. B symptoms seen in 124 (45%) Early Stages (I II) 130 (52%) patients, while advanced (III 1V) 119 (48%) Bulky disease (>7.5 cm) 30% cases, bone marrow involved 12%. Extranodal involvement present 35% cases. Cell origin available 160 (60%) 88 (55%) germinal center 72 activated origin. distribution according international index (IPI) as follows: low risk 40%, intermediate 45%, high 15%. Rituximab used 45% overall rate 84% complete (CR) 70.5%. CR rates better RCHOP compared CHOP (77% vs. 61.5%, P = 0.001) good-risk IPI (83.3% 65.2%, < intermediate- high-risk IPI. Median follow-up period 24 months, 2-year event-free survival (EFS) 70%. presence symptoms, IPI, failure attain CR, poor PS, nonrituximab-based chemotherapy significantly associated lower EFS.This first India, investigated impact or without rituximab context Adding showed EFS irrespective